Non-alcoholic fatty liver disease/non-alcoholic steatohepatitis (NAFLD/NASH): Treatment

Best Practice and Research: Clinical Gastroenterology

Volumn 18, Issue 6 SPEC.ISS., 2004, Pages 1105-1116

  Bugianesi, Elisabetta ^a   Marzocchi, Rebecca ^b   Villanova, Nicola ^b   Marchesini, Giulio ^b  

^a UNIVERSITY OF TURIN   (Italy)

^b UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

Anti oxidants; Fatty liver; Insulin sensitizing agents; Lifestyle; Treatment

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ALPHA TOCOPHEROL; ATORVASTATIN; BETAINE; BEZAFIBRATE; CLOFIBRATE; GEMFIBROZIL; INSULIN SENSITIZING AGENT; METFORMIN; NICOTINAMIDE; PIOGLITAZONE; PLACEBO; ROSIGLITAZONE; TAMOXIFEN; TAURINE; TETRAHYDROLIPSTATIN; TROGLITAZONE; URSODEOXYCHOLIC ACID;

ANTIOXIDANT ACTIVITY; CELL PROTECTION; CLINICAL TRIAL; DIET THERAPY; DISEASE COURSE; DRUG ACTIVITY; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; EXERCISE; HISTOLOGY; HUMAN; INSULIN RESISTANCE; INSULIN SENSITIVITY; LIPID ABSORPTION; LIPID STORAGE; LIVER TOXICITY; NONALCOHOLIC FATTY LIVER; NUTRITIONAL SUPPORT; OXIDATIVE STRESS; PHLEBOTOMY; REVIEW; WEIGHT REDUCTION;

EID: 8744256459     PISSN: 15216918     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bpg.2004.06.025     Document Type: Review

References (50)

1. B.A. Neuschwander-Tetri S.H. Caldwell Nonalcoholic steatohepatitis: summary of an AASLD Single Topic Conference Hepatology 37 2003 1202-1219
2. American Gastroenterological Association American Gastroenterological Association medical position statement: Nonalcoholic fatty liver disease Gastroenterology 123 2002 1702-1704
3. T. Gramlich D.E. Kleiner A.J. McCullough et al. Pathologic features associated with fibrosis in nonalcoholic fatty liver disease Hum Pathol 35 2004 196-199
4. P. Mofrad M.J. Contos M. Haque et al. Clinical and histologic spectrum of nonalcoholic fatty liver disease associated with normal ALT values Hepatology 37 2003 1286-1292
5. T. Poynard P. Mathurin C.L. Lai et al. A comparison of fibrosis progression in chronic liver diseases J Hepatol 38 2003 257-265
6. Y. Falck-Ytter Z.M. Younossi G. Marchesini A.J. McCullough Clinical features and natural history of nonalcoholic steatosis syndromes Semin Liver Dis 21 2001 17-26
7. B. Isomaa P. Almgren T. Tuomi et al. Cardiovascular morbidity and mortality associated with the metabolic syndrome Diabetes Care 24 2001 683-689
8. T. Andersen C. Gluud M.B. Franzmann P. Christoffersen Hepatic effects of dietary weight loss in morbidly obese subjects J Hepatol 12 1991 224-229
9. P. Vajro A. Fontanella C. Perna et al. Persistent hyperaminotransferasemia resolving after weight reduction in obese children J Pediatr 125 1994 239-241
10. T. Ueno H. Sugawara K. Sujaku et al. Therapeutic effects of restricted diet and exercise in obese patients with fatty liver J Hepatol 27 1997 103-107
11. A. Franzese P. Vajro A. Argenziano et al. Liver involvement in obese children. Ultrasonography and liver enzyme levels at diagnosis and during follow-up in an Italian population Dig Dis Sci 42 1997 1428-1432
12. I.E. Hickman J.R. Jonsson J.B. Prins et al. Modest weight loss and physical activity in overweight patients with chronic liver disease results in sustained improvements in alanine aminotransferase, fasting insulin, and quality of life Gut 53 2004 413-419
13. J. Laurin K.D. Lindor J.S. Crippin et al. Ursodeoxycholic acid or clofibrate in the treatment of non-alcohol-induced steatohepatitis: A pilot study Hepatology 23 1996 1464-1467
14. K. Obinata T. Maruyama M. Hayashi et al. Effect of taurine on the fatty liver of children with simple obesity Adv Exp Med Biol 403 1996 607-613
15. P. Vajro A. Franzese G. Valerio et al. Lack of efficacy of ursodeoxycholic acid for the treatment of liver abnormalities in obese children J Pediatr 136 2000 739-743
16. K.D. Lindor K.V. Kowdley E.J. Heathcote et al. Ursodeoxycholic acid for treatment of nonalcoholic steatohepatitis: Results of a randomized trial Hepatology 39 2004 770-778
17. W.J. Coyle N. Delaney A. Yoshihashi P. Lawson Metformin treatment in patients with nonalcoholic steatohepatitis normalizes LFTs and improves histology Gastroenterology 116 1999 1198-1199
18. G. Marchesini M. Brizi G. Bianchi et al. Metformin in non-alcoholic steatohepatitis Lancet 358 2001 893-894
19. S.H. Caldwell E.E. Hespenheide J.A. Redick et al. A pilot study of a thiazolidinedione, troglitazone, in nonalcoholic steatohepatitis Am J Gastroenterol 96 2001 519-525
20. B.A. Neuschwander-Tetri E.M. Brunt K.R. Wehmeier et al. Improved nonalcoholic steatohepatitis after 48 weeks of treatment with the PPAR-gamma ligand rosiglitazone Hepatology 38 2003 1008-1017
21. A. Uygun A. Kadayifci A.T. Isik et al. Metformin in the treatment of patients with non-alcoholic steatohepatitis Aliment Pharmacol Ther 19 2004 537-544
22. K. Promrat G. Lutchman G.I. Uwaifo et al. A pilot study of pioglitazone treatment for nonalcoholic steatohepatitis Hepatology 39 2004 188-196
23. M. Basaranoglu O. Acbay A. Sonsuz A controlled trial of gemfibrozil in the treatment of patients with nonalcoholic steatohepatitis J Hepatol 31 1999 384
24. M. Kiyici M. Gulten S. Gurel et al. Ursodeoxycholic acid and atorvastatin in the treatment of nonalcoholic steatohepatitis Can J Gastroenterol 17 2003 713-718
25. J.E. Lavine Vitamin E treatment of nonalcoholic steatohepatitis in children: A pilot study J Pediatr 136 2000 734-738
26. F. Miglio L.C. Rovati A. Santoro I. Setnikar Efficacy and safety of oral betaine glucuronate in non-alcoholic steatohepatitis. A double-blind, randomized, parallel-group, placebo-controlled prospective clinical study Arzneimittelforschung 50 2000 722-727
27. M.F. Abdelmalek P. Angulo R.A. Jorgensen et al. Betaine, a promising new agent for patients with nonalcoholic steatohepatitis: Results of a pilot study Am J Gastroenterol 96 2001 2711-2717
28. T. Hasegawa M. Yoneda K. Nakamura Plasma transforming growth factor-beta1 level and efficacy of alpha-tocopherol in patients with non-alcoholic steatohepatitis: A pilot study Aliment Pharmacol Ther 15 2001 1667-1672
29. M. Kugelmas D.B. Hill B. Vivian et al. Cytokines and NASH: A pilot study of the effects of lifestyle modification and vitamin E Hepatology 38 2003 413-419
30. P. Vajro C. Mandato A. Franzese et al. Vitamin E treatment in pediatric obesity-related liver disease: A randomized study J Pediatr Gastroenterol Nutr 38 2004 48-55
31. M. Yoneda T. Hasegawa K. Nakamura et al. Vitamin E therapy in patients with NASH Hepatology 39 2004 568
32. F.S. Facchini N.W. Hua R.A. Stoohs Effect of iron depletion in carbohydrate-intolerant patients with clinical evidence of nonalcoholic fatty liver disease Gastroenterology 122 2002 931-939
33. S.A. Harrison S. Ramrakhiani E.M. Brunt et al. Orlistat in the treatment of NASH: A case series Am J Gastroenterol 98 2003 926-930
34. M. Vallis L. Ruggiero G. Greene et al. Stages of change for healthy eating in diabetes: Relation to demographic, eating-related, health care utilization, and psychosocial factors Diabetes Care 26 2003 1468-1474
35. J.O. Prochaska W.F. Velicer The transtheoretical model of health behavior change Am J Health Promot 12 1997 38-48
36. K.N. Lazaridis G.J. Gores K.D. Lindor Ursodeoxycholic acid 'mechanisms of action and clinical use in hepatobiliary disorders' J Hepatol 35 2001 134-146
37. G. Marchesini M. Brizi A.M. Morselli-Labate et al. Association of nonalcoholic fatty liver disease with insulin resistance Am J Med 107 1999 450-455
38. B. Vozarova N. Stefan R.S. Lindsay et al. High alanine aminotransferase is associated with decreased hepatic insulin sensitivity and predicts the development of type 2 diabetes Diabetes 51 2002 1889-1895
39. H.Z. Lin S.Q. Yang C. Chuckaree et al. Metformin reverses fatty liver disease in obese, leptin-deficient mice Nat Med 6 2000 998-1003
40. D.R. Matthews J.P. Hosker A.S. Rudenski et al. Homeostasis model assessment: Insulin resistance and beta-cell function from plasma fasting glucose and insulin concentrations in man Diabetologia 28 1985 412-419
41. R. Urso U. Visco-Comandini Metformin in non-alcoholic steatohepatitis Lancet 359 2002 355-356
42. B.A. Neuschwander-Tetri E.M. Brunt K.R. Wehmeier et al. Interim results of a pilot study demonstrating the early effects of the PPAR-gamma ligand rosiglitazone on insulin sensitivity, aminotransferases, hepatic steatosis and body weight in patients with non-alcoholic steatohepatitis J Hepatol 38 2003 434-440
43. R.W. Nesto D. Bell R.O. Bonow et al. Thiazolidinedione use, fluid retention, and congestive heart failure: A consensus statement from the American Heart Association and American Diabetes Association Diabetes Care 27 2004 256-263
44. T. Saibara S. Onishi Y. Ogawa et al. Bezafibrate for tamoxifen-induced non-alcoholic steatohepatitis Lancet 353 1999 1802
45. Z.M. Younossi T. Gramlich B.R. Bacon et al. Hepatic iron and nonalcoholic fatty liver disease Hepatology 30 1999 847-850
46. E. Bugianesi P. Manzini S. D'Antico et al. Relative contribution of iron burden, HFE mutations and insulin resistance to fibrosis in nonalcoholic fatty liver Hepatology 39 2004 179-187
47. E. Ferrannini Insulin resistance, iron, and the liver Lancet 355 2000 2181-2182
48. A. Guillygomarc'h M.H. Mendler R. Moirand et al. Venesection therapy of insulin resistance-associated hepatic iron overload J Hepatol 35 2001 344-349
49. E. Bugianesi C. Zannoni E. Vanni et al. Non-alcoholic fatty liver and insulin resistance: A cause-effect relationship? Dig Liver Dis 36 2004 165-173
50. J.M. Clark F.L. Brancati Negative trials in nonalcoholic steatohepatitis: Why they happen and what they teach us Hepatology 39 2004 602-603